According to our latest study on “Chemotherapy-Induced Peripheral Neuropathy Market Forecast to 2028 - COVID-19 Impact and Global Analysis - Drug Class (Steroids, Antidepressants, Anti-Seizures, and Narcotics) and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)," the market is expected to grow from US$ 813.48 million in 2021 to US$ 1,174.26 million by 2028; it is estimated to grow at a CAGR of 5.4% from 2021 to 2028. The report highlights the key factors driving the market and prominent players with their developments. The growth of the chemotherapy-induced peripheral neuropathy market is mainly driven by an increase in the prevalence of cancer and a rising preference for chemotherapy. Additionally, the growing number of clinical trials for chemotherapeutic drugs is likely to emerge as a significant trend in the market during the forecast period. However, the lack of consolidated guidelines for chemotherapy hampers the chemotherapy-induced peripheral neuropathy market growth.
Disturbances in supply chains and tremendous demand for efficient treatments for the therapy of COVID-19 put the healthcare research industry in Asia Pacific in a crucial situation in 2020. Prohibitive measures were taken to control the spread of this pandemic. The socioeconomics was severely affected, resulting in inflation, GDP drop, and unemployment surge. Healthcare providers had to postpone the cancer screening, diagnosis and treatment appointments to attend to COVID-19 patients on priority, which led to the decline in demand for chemotherapy among cancer patients. Drug companies continue their research to find the drug candidates effective against chemotherapy-induced peripheral neuropathy. For instance, in March 2022, Asahi Kasei Pharma announced the commencement of the Japan-US international phase 1 study of ART-123 (generic name: thrombomodulin alfa, marketed as Recomodulin Injection in Japan) for the prevention of sensory symptoms of chemotherapy-induced peripheral neuropathy, which is being conducted jointly with Veloxis Pharmaceuticals, Inc., wholly-owned subsidiary of Asahi Kasei Corp. For the chemotherapy treatment, the COVID-19 pandemic must serve as a driver for the more rapid uptake of technology and techniques, enabling shorter treatments. To ensure that cancer patients have access to modern chemotherapy both during and after the pandemic, the EU countries are emphasizing the reinforcement of their healthcare infrastructures.
Lucrative Regions for Chemotherapy Induced Peripheral Neuropathy Market
Chemotherapy Induced Peripheral Neuropathy Market Global Report 2028
Download Free Sample
Chemotherapy Induced Peripheral Neuropathy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Class (Steroids, Antidepressants, Anti-Seizure, and Narcotics) and Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy)
Chemotherapy Induced Peripheral Neuropathy Market Global Report 2028
Download Free SampleChemotherapy Induced Peripheral Neuropathy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Class (Steroids, Antidepressants, Anti-Seizure, and Narcotics) and Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy)
Based on drug class, the chemotherapy-induced peripheral neuropathy market is segmented into steroids, anti-seizure, antidepressants, and narcotics. The steroids segment held the largest share of the market in 2021. Moreover, the anti-seizure segment is anticipated to register the highest CAGR of 6.2% in the market during the forecast period. Steroids are a man-made version of hormones that are made naturally in the human body. Steroids are designed to act like these hormones to reduce inflammation. They’re also known as corticosteroids and are different than anabolic steroids used by bodybuilders and athletes. An increase in the geriatric populace and a rise in government initiatives for better health services is mainly fueling the growth of the steroids market. The demand for steroids is also being driven by the increasing prevalence of cancer and CIPM. Nowadays steroid manufacturing occupies a prominent place in the pharmaceuticals industry. A rise in drug resistance and the low cost of products further contribute to the growth of the chemotherapy-induced peripheral neuropathy market for steroid segment.
Regenacy Pharmaceuticals, Inc.; Asahi Kasei Pharma Corporation.; Novaremed; Makscientific, Llc; Wex Pharmaceuticals Inc.; Sova Pharmaceuticals, Inc.; Kineta, Inc.; Aptinyx Inc.; Apexian Pharmaceuticals, Inc.; and Winsantor, Inc. are among the leading companies in the chemotherapy-induced peripheral neuropathy market.
The report segments the chemotherapy-induced peripheral neuropathy market as follows:
The chemotherapy-induced peripheral neuropathy market is segmented on the basis of drug class, distribution channel, and geography. The market, by drug class, is segmented into steroids, antidepressants, anti-seizures, and narcotics. The chemotherapy-induced peripheral neuropathy market, based on distribution channel, is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. By geography, the chemotherapy-induced peripheral neuropathy market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com